Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates: Design of a Retrospective Cohort Study

Jennifer G. Jetton, Ronnie Guillet, David J. Askenazi, Lynn Dill, Judd Jacobs, Alison L. Kent, David T. Selewski, Carolyn L. Abitbol, Fredrick J. Kaskel, Maroun J. Mhanna, Namasivayam Ambalavanan, Jennifer R. Charlton, the Neonatal Kidney Collaborative, Ayse Akcan Arikan, Alok Bhutada, Elizabeth Bonachea, Louis Boohaker, Patrick D. Brophy, Aftab S. Chishti, Tarah T. Colaizy, F. Sessions Cole, Carl D’Angio, T. Keefe Davis, Marissa DeFreitas, Joshua Dower, Shahnaz Duara, Jeffery Fletcher, Mamta Fuloria, Jason Gien, Katja M. Gist, Stuart L. Goldstein, Russell Griffin, Mina H. Hanna, Sangeeta Hingorani, Susan Ingraham, Catherine Joseph, Surender Khokhar, Jonathan M. Klein, Deepak Kumar, Juan C. Kupferman, John Mahan, Cherry Mammen, Ayesa Mian, Lawrence Milner, Arwa Nada, Amy T. Nathan, Robin Ohls, Sofia Perazzo, Erin Rademacher, Rupesh Raina, Shantanu Rastogi, Patricio E. Ray, Kimberly Reidy, Mary Revenis, Christopher J. Rhee, Smriti Rohatgi, Subrata Sarkar, Sidharth Kumar Sethi, Alexandra Smith, Danielle E. Soranno, Shanthy Sridhar, Amy Staples, Michelle Starr, Jonathan R. Swanson, Anne Synnes, Sanjay Wazir, Pia Wintermark, Craig S. Wong, Robert Woroniecki, Michael Zappitelli

Acute kidney injury (AKI) affects ~30% of hospitalized neonates. Critical to advancing our understanding of neonatal AKI is collaborative research among neonatologists and nephrologists. The Neonatal Kidney Collaborative (NKC) is an international, multidisciplinary group dedicated to investigating neonatal AKI. The AWAKEN study (Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates) was designed to describe the epidemiology of neonatal AKI, validate the definition of neonatal AKI, identify primary risk factors for neonatal AKI, and investigate the contribution of fluid management to AKI events and short-term outcomes. The NKC was established with at least one pediatric nephrologist and neonatologist from 24 institutions in 4 countries (USA, Canada, Australia, and India). A Steering Committee and four subcommittees were created. The database subcommittee oversaw the development of the web-based database (MediData Rave™) that captured all NICU admissions from 1/1/14 to 3/31/14. Inclusion and exclusion criteria were applied to eliminate neonates with a low likelihood of AKI. Data collection included: (1) baseline demographic information; (2) daily physiologic parameters and care received during the first week of life; (3) weekly "snapshots"; (4) discharge information including growth parameters, final diagnoses, discharge medications, and need for renal replacement therapy; and (5) all serum creatinine values. AWAKEN was proposed as human subjects research. The study design allowed for a waiver of informed consent/parental permission. NKC investigators will disseminate data through peer-reviewed publications and educational conferences. The purpose of this publication is to describe the formation of the NKC, the establishment of the AWAKEN cohort and database, future directions, and a few "lessons learned." The AWAKEN database includes ~325 unique variables and >4 million discrete data points. AWAKEN will be the largest, most inclusive neonatal AKI study to date. In addition to validating the neonatal AKI definition and identifying risk factors for AKI, this study will uncover variations in practice patterns related to fluid provision, renal function monitoring, and involvement of pediatric nephrologists during hospitalization. The AWAKEN study will position the NKC to achieve the long-term goal of improving the lives, health, and well-being of newborns at risk for kidney disease.